<DOC>
	<DOCNO>NCT00134004</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine cyclophosphamide , radiation therapy donor bone marrow transplant help stop growth cancer cell . Giving chemotherapy radiation therapy transplant also stop patient 's immune system reject donor 's bone marrow stem cell . The donated stem cell may replace patient 's immune system cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine cyclophosphamide together total-body irradiation work treat patient undergo donor bone marrow transplant hematologic cancer .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Total-Body Irradiation Treating Patients Who Are Undergoing Donor Bone Marrow Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine transplant-related mortality , risk relapse , progression-free survival patient standard- high-risk hematologic malignancy undergo nonmyeloablative conditioning comprise fludarabine , cyclophosphamide , total-body irradiation follow HLA-haploidentical allogeneic bone marrow transplantation . - Determine donor hematopoietic chimerism patient ' peripheral blood 30 , 60 , 180 day transplantation . - Determine hematologic nonhematologic toxic effect regimen patient . - Determine , feasible , surface expression HLA molecules death receptor , sensitivity cytotoxic lymphocyte , expression anti-apoptotic gene ( e.g. , Bcl-2 , Bcl-xL , X-IAP , c-FLIP ) cancer cell patient relapse treatment regimen . OUTLINE : This multicenter study . Patients stratify accord risk relapse ( standard [ define ≤ 30 % risk ] vs high [ define ≥ 70 % risk ] ) . - Nonmyeloablative conditioning regimen : Patients receive fludarabine IV 30 minute day -6 -2 cyclophosphamide IV 1-2 hour day -6 -5 . Patients undergo total body irradiation day -1 . - Allogeneic bone marrow transplantation : Patients undergo donor bone marrow infusion day 0 . - Post-transplantation therapy : Patients receive cyclophosphamide IV 1-2 hour day 3 4 . - Graft-vs-host disease prophylaxis : Beginning day 5 , patient receive oral mycophenolate mofetil 3 time daily day 35 tacrolimus IV ( change orally ) twice daily day 180 . Treatment continue absence disease progression . After completion study transplantation , patient follow day 30 , 60 , 100 , 180 ; 1 year ; annually 4 additional year . PROJECTED ACCRUAL : A total 75-100 patient accrue study within 3-4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Acute leukemia In second subsequent complete remission ( CR ) , define absence abnormal blast population flow cytometry In first CR follow poorrisk cytogenetic feature : Alteration chromosome 5 7 Multiple abnormality Philadelphia chromosome positive Chronic phase chronic myelogenous leukemia ( CML ) In first chronic phase refractory interferon alfa imatinib mesylate In second subsequent chronic phase Chronic lymphocytic leukemia , meet 1 follow criterion : Received prior chemotherapy nucleoside analog remission last &lt; 6 month Received 1 prior therapy follow highrisk feature : Cytogenetic abnormality 17p , 11q Mutations Zap70 gene Somatically unmutated immunoglobulin heavy chain variable region gene Hodgkin 's lymphoma Ineligible autologous stem cell transplantation ( SCT ) due follow exclusion factor : LVEF &lt; 45 % FEV_1 FVC &lt; 50 % predict ( 75 % predict patient prior thoracic mantle radiotherapy ) Total bilirubin &gt; 2.0 mg/dL ( unless document Gilbert 's disease ) Creatinine &gt; 2.0 mg/dL NonHodgkin 's lymphoma ( NHL ) Lowgrade NHL allow provide patient remission duration &lt; 1 year administration establish , multiagent chemotherapy regimen ( e.g. , CVP , CHOP , rituximab combination CHOP ) Intermediate highgrade NHL allow provide patient ineligible autologous SCT accord criterion list Multiple myeloma Myelodysplastic syndrome Paroxysmal nocturnal hemoglobinuria Chronic myeloproliferative disorder CML , include follow : Chronic myelomonocytic leukemia Agnogenic myeloid metaplasia ( myeloid metaplasia myelofibrosis ) , hemoglobin &lt; 10 g/dL OR WBC &lt; 4,000/mm^3 &gt; 30,000/mm^3 Polycythemia vera essential thrombocythemia `` spent '' phase , history 2 following : Marrow fibrosis Splenomegaly Cytopenia ( i.e. , absolute neutrophil count &lt; 1,500/mm^3 , platelet count &lt; 100,000/mm^3 , hemoglobin &lt; 10 g/dL ) Polycythemia vera essential thrombocythemia transformation myelodysplastic syndrome acute myeloid leukemia ( require treatment achieve &lt; 20 % blast marrow ) No smolder myeloma Patients acute myeloid leukemia myelodysplastic syndrome must comprehensive cytogenetic evaluation bone marrow specimen active disease Ineligible refuse bone marrow transplantation HLAmatched sibling unrelated donor Ineligible refuse autologous SCT Must HLA mismatch ( i.e. , 3/6 , 4/6 , 5/6 ) relate ( firstdegree relative ) * donor available Donor ≥ 18 year age NOTE : *Patients inherit recombinant HLA haplotype may receive marrow parent whose gamete recombination occur NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 6 month 74 year Performance status ECOG 01 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic See Disease Characteristics Bilirubin &lt; 3.1 mg/dL Renal See Disease Characteristics Cardiovascular See Disease Characteristics LVEF ≥ 35 % Pulmonary See Disease Characteristics FEV_1 FVC ≥ 40 % predict patient without prior thoracic mantle radiotherapy ( 60 % predict patient prior thoracic mantle radiotherapy ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative Geographically accessible No debilitate medical psychiatric illness would preclude give informed consent receive optimal treatment followup PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior transfusion donor Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>